Status:
COMPLETED
Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
HIV Infections
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this pilot study is to evaluate efficacy and safety of addition of IL-2 to pegylated interferon alpha 2a and ribavirin in HIV-HCV coinfected patients non-responders after three months o...
Detailed Description
This pilot study evaluate efficacy and safety of addition of IL-2 to pegylated interferon alpha 2a and ribavirin in HIV-HCV coinfected patients non-responders after three months of standard therapy wi...
Eligibility Criteria
Inclusion
- HIV-1 infection and HCV infection
- Naive of ribavirin
- CD4 higher than 300 if pretreated by antiretroviral therapy or higher than 400 if naive of antiretroviral therapy
- Signed informed consent
Exclusion
- Cirrhosis (histological fibrosis score F4 in Metavir score)
- Other liver disease
- Pregnancy
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00196586
Start Date
April 1 2003
End Date
November 1 2006
Last Update
November 16 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Européen Georges Pompidou
Paris, France, 75015